3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Other hematologic neoplasm
1
Lymphoid
1
Gynecologic
1
Breast
1
Conditions
Breast Neoplasms
29
Neoplasms
5
Glioma
4
Ovarian Neoplasms
3
Neoplasm Metastasis
3
Melanoma
3
Glioblastoma
3
Rhabdoid Tumor
2
Neoplasms, Germ Cell and Embryonal
2
Medulloblastoma
2
Lymphoma
2
Liposarcoma
2
Fallopian Tube Neoplasms
2
Diffuse Intrinsic Pontine Glioma
2
Brain Neoplasms
2
Astrocytoma
2
Thymus Neoplasms
1
Teratoma
1
Solid Tumors Harboring a BRAF V600 Mutation
1
Sarcoma, Synovial
1
Sarcoma
1
Recurrence
1
Pyloric Stenosis, Hypertrophic
1
Prostatic Neoplasms
1
Pinealoma
1
Osteitis Deformans
1
Oligodendroglioma
1
Non functioning pancreatic endocrine tumor
1
Neurofibrosarcoma
1
Neuroendocrine Tumors
1
Interventions
Pemetrexed
23
Cisplatin
19
Nivolumab
8
Gemcitabine
7
Ipilimumab
6
Carboplatin
6
pembrolizumab
4
Bevacizumab
4
tazemetostat
3
durvalumab
3
Fluorouracil
3
Drug Therapy
3
spartalizumab
2
olaparib
2
niraparib
2
budigalimab
2
belinostat
2
anetumab ravtansine
2
amatuximab
2
Vinorelbine
2
Radiotherapy, Intensity-Modulated
2
Paclitaxel
2
PM 01183
2
Oxaliplatin
2
Imatinib Mesylate
2
Everolimus
2
Erlotinib Hydrochloride
2
Doxorubicin
2
Cyclophosphamide
2
venetoclax
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Mesothelioma
×
ribociclib
×
Clear all
NCT02187783
2019-07-18
SIGNATURE
Novartis
Phase 2
Completed
106 enrolled
16 charts